HC Wainwright Has Lowered Expectations for Vertex ... - MarketBeat

HC Wainwright Has Lowered Expectations For Vertex ... - MarketBeat

1 week from now

Dec 20, 2024  · The company has a market capitalization of $102.15 billion, a PE ratio of -199.32 and a beta of 0.36. Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of …

marketbeat.com

Barclays Has Lowered Expectations For Vertex ... - MarketBeat

1 week from now

Dec 20, 2024  · HC Wainwright decreased their price objective on Vertex Pharmaceuticals from $600.00 to $535.00 and set a "buy" rating on the stock in a research report on Friday. ...

marketbeat.com

HC Wainwright Has Lowered Expectations For Vertex …

1 week from now

Dec 22, 2024  · Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price reduced by equities research analysts at HC Wainwright from $600.00 to $535.00 in a …

defenseworld.net

HC Wainwright Issues Pessimistic Forecast For Vertex …

1 week from now

Dec 23, 2024  · Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective cut by HC Wainwright from $600.00 to $535.00 in a research note released on Friday, …

americanbankingnews.com

Truist Financial Has Lowered Expectations For Vertex …

1 week from now

Dec 25, 2024  · Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The firm has a market capitalization of $105.12 billion, a PE ratio of -205.12 and a beta of 0.36.

etfdailynews.com

Wells Fargo & Company Issues Pessimistic Forecast For Vertex ...

1 week from now

5 days ago  · NASDAQ VRTX opened at $409.56 on Friday. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The stock has a 50-day moving average …

defenseworld.net

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut To …

1 week from now

Dec 22, 2024  · The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of …

americanbankingnews.com

Vertex Price Target Lowered To $535 From $600 At H.C. Wainwright

1 week from now

Dec 20, 2024  · H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $535 from $600 and keeps a Buy rating on the shares after the …

nasdaq.com

Bank Of America Has Lowered Expectations For Vertex

1 week from now

Dec 19, 2024  · HC Wainwright restated a "buy" rating and set a $600.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday, October 21st. ... Vertex …

marketbeat.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $500.00

1 week from now

Dec 23, 2024  · HC Wainwright lowered their price objective on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a "buy" rating on the stock in a research report on Friday. ...

marketbeat.com

Barclays Has Lowered Expectations For Revance ... - ETF Daily News

1 week from now

Dec 25, 2024  · Revance Therapeutics stock opened at $3.08 on Monday. The firm has a market cap of $321.52 million, a PE ratio of -1.60 and a beta of 0.82. The stock’s fifty day moving …

etfdailynews.com

Bank Of America Has Lowered Expectations For Immunovant

1 week from now

2 days ago  · Wells Fargo & Company lowered their price target on Immunovant from $47.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, …

marketbeat.com

Rhythm Pharmaceuticals’ (RYTM) Buy Rating Reaffirmed At HC …

1 week from now

Dec 25, 2024  · RYTM stock opened at $55.85 on Monday. The stock has a market cap of $3.43 billion, a price-to-earnings ratio of -12.90 and a beta of 2.14. The company has a fifty day …

etfdailynews.com

HC Wainwright Has Lowered Expectations For Electrovaya

1 week from now

Dec 13, 2024  · HC Wainwright reduced their price target on shares of Electrovaya from $16.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday. ... HC Wainwright …

marketbeat.com

Cytokinetics (NASDAQ:CYTK) Earns “Buy” Rating From HC …

1 week from now

Dec 23, 2024  · Shares of NASDAQ CYTK opened at $48.87 on Friday. Cytokinetics has a fifty-two week low of $36.24 and a fifty-two week high of $110.25. The company has a market cap …

etfdailynews.com

Franco-Nevada (NYSE:FNV) Given New $155.00 Price Target At HC …

1 week from now

Dec 20, 2024  · HC Wainwright dropped their price objective on Franco-Nevada from $200.00 to $155.00 and set a "buy" rating on the stock in a research report on Friday. ... The company …

marketbeat.com

HC Wainwright Reaffirms "Buy" Rating For Vericel (NASDAQ:VCEL)

1 week from now

2 days ago  · HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Vericel in a research note on Wednesday. ... The business had revenue of $57.91 million for …

marketbeat.com

PotlatchDeltic (NASDAQ:PCH) Stock Rating Upgraded By …

1 week from now

Dec 25, 2024  · PotlatchDeltic has a 12-month low of $37.06 and a 12-month high of $50.04. The firm has a market cap of $3.11 billion, a price-to-earnings ratio of 188.29 and a beta of 1.14.

etfdailynews.com

HC Wainwright Reaffirms Buy Rating For Alnylam ... - MarketBeat

1 week from now

4 days ago  · HC Wainwright reaffirmed a "buy" rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday. ... estimate of ($0.51) by ($0.36). …

marketbeat.com

Plug Power (NASDAQ:PLUG) Shares Down 2.6% - Time To Sell?

1 week from now

6 hours ago  · The company traded as low as $2.55 and last traded at $2.64. 52,953,341 shares traded hands during trading, a decline of 33% from the average session volume of 78,753,039 …

marketbeat.com

Needham & Company LLC Has Lowered Expectations For Avadel

1 week from now

Jan 9, 2025  · HC Wainwright cut their price objective on Avadel Pharmaceuticals from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, November …

marketbeat.com